Optimising monitoring in the management of Crohn's disease: A physician's perspective

Journal of Crohn's and Colitis

Volumn 7, Issue 8, 2013, Pages 653-669

  Papay, Pavol ^a   Ignjatovic, Ana ^b   Karmiris, Konstantinos ^c   Amarante, Heda ^d   Milheller, Pal ^e   Feagan, Brian ^f   D'Haens, Geert ^g   Marteau, Philippe ^h   Reinisch, Walter ^a   Sturm, Andreas ⁱ   Steinwurz, Flavio ^j   Egan, Laurence ^k   Panés, Julián ^l   Louis, Edouard ^m   Colombel, Jean Frédéric ⁿ   Panaccione, Remo ^o  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c Venizelion General Hospital   (Greece)

^d FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^e SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^f ROBARTS RESEARCH INSTITUTE   (Canada)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ Waldfriede Hospital   (Germany)

^j HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^k NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^l INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^m UNIVERSITY OF LIÈGE   (Belgium)

ⁿ LILLE UNIVERSITY HOSPITAL   (France)

^o UNIVERSITY OF CALGARY   (Canada)

more..

Author keywords

Biomarkers; Diagnosis; Disease activity index; Endoscopy; Imaging; Monitoring

Indexed keywords

ACUTE PHASE PROTEIN; AZATHIOPRINE; C REACTIVE PROTEIN; CALGRANULIN; INFLIXIMAB; LACTOFERRIN; STEROID;

CAPSULE ENDOSCOPY; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ECHOGRAPHY; FOLLOW UP; HARVEY BRADSHAW INDEX; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PATIENT MONITORING; PHYSICIAN; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; REVIEW; STEROID THERAPY; SYMPTOM ASSESSMENT; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; WELLBEING;

ANNUAL EXCHANGE ON THE ADVANCES IN INFLAMMATORY BOWEL DISEASE; BIOMARKERS; C-REACTIVE PROTEIN; CD; CDAI; CDEIS; COMPUTED TOMOGRAPHY; CROHN'S DISEASE; CROHN'S DISEASE ACTIVITY INDEX; CROHN'S DISEASE ENDOSCOPIC INDEX OF SEVERITY; CRP; CT; DIAGNOSIS; DISEASE ACTIVITY INDEX; ENDOSCOPY; GASTROINTESTINAL; GI; HARVEY-BRADSHAW INDEX; HBI; IBD; IBD AHEAD; IBDQ; IMAGING; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; INTERNATIONAL STEERING COMMITTEE; ISC; MAGNETIC RESONANCE IMAGING; MONITORING; MRI; QOL; QUALITY OF LIFE; SBCE; SBFT; SES-CD; SIMPLE ENDOSCOPIC SCORE FOR CROHN'S DISEASE; SMALL-BOWEL CAPSULE ENDOSCOPY; SMALL-BOWEL FOLLOW-THROUGH; TNF; TUMOUR NECROSIS FACTOR;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; FECES; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84880036903     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.02.005     Document Type: Review

References (124)

1. Cellier C., Sahmoud T., Froguel E., Adenis A., Belaiche J., Bretagne J.F., et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1994, 35:231-235.
2. Pariente B., Cosnes J., Danese S., Sandborn W.J., Lewin M., Fletcher J.G., et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011, 17:1415-1422.
3. Froslie K.F., Jahnsen J., Moum B.A., Vatn M.H. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
4. Colombel J.F., Rutgeerts P., Sandborn W.J., Yang M., Lomax K.G., Pollack P.F., et al. Deep remission predicts long-term outcomes for adalimumab-treated patients with Crohn's disease: data from EXTEND. Gut 2010, 59(Suppl. 3):A80. [Abstract OP371].
5. Peyrin-Biroulet L., Loftus E.V., Colombel J.F., Sandborn W.J. Early Crohn disease: a proposed definition for use in disease-modification trials. Gut 2010, 59:141-147.
6. Rutgeerts P., Van Assche G., Sandborn W.J., Wolf D.C., Geboes K., Colombel J.F., et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012, 142:1102-1111.
7. Sandborn W.J., Panaccione R., Thakker R., Lomax K.G., Chen N., Mulani P.M., et al. Duration of Crohn's disease affects mucosal healing in adalimumab-treated patients: results from EXTEND. J Crohns Colitis 2010, 4:S36. [Abstract PO69].
8. Panaccione R., Hibi T., Peyrin-Biroulet L., Schreiber S. Implementing changes in clinical practice to improve the management of Crohn's disease. J Crohns Colitis 2012, 6(Suppl. 2):S235-S242.
9. Best W.R., Becktel J.M., Singleton J.W., Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70:439-444.
10. Harvey R.F., Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1980, 1:514.
11. Irvine E.J. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999, 28:S23-S27.
12. Guyatt G., Mitchell A., Irvine E.J., Singer J., Williams N., Goodacre R., et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989, 96:804-810.
13. Freeman H.J. Use of the Crohn's disease activity index in clinical trials of biological agents. World J Gastroenterol 2008, 14:4127-4130.
14. van Hees P.A., van Elteren P.H., van Lier H.J., van Tongeren J.H. An index of inflammatory activity in patients with Crohn's disease. Gut 1980, 21:279-286.
15. Irvine E.J., Feagan B., Rochon J., Archambault A., Fedorak R.N., Groll A., et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994, 106:287-296.
16. Mary J.Y., Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989, 30:983-989.
17. Daperno M., D'Haens G., Van Assche G., Baert F., Bulois P., Maunoury V., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004, 60:505-512.
18. Rutgeerts P., Geboes K., Vantrappen G., Beyls J., Kerremans R., Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990, 99:956-963.
19. Chamouard P., Richert Z., Meyer N., Rahmi G., Baumann R. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:882-887.
20. Langhorst J., Elsenbruch S., Koelzer J., Rueffer A., Michalsen A., Dobos G.J. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008, 103:162-169.
21. Reinisch W., Wang Y., Oddens B.J., Link R. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 2012, 35:568-576.
22. Solem C.A., Loftus E.V., Tremaine W.J., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:707-712.
23. Vermeire S., Van Assche G., Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:661-665.
24. Schoepfer A.M., Trummler M., Seeholzer P., Seibold-Schmid B., Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008, 14:32-39.
25. Schoepfer A.M., Beglinger C., Straumann A., Trummler M., Vavricka S.R., Bruegger L.E., et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010, 105:162-169.
26. Gisbert J.P., Bermejo F., Perez-Calle J.L., Taxonera C., Vera I., McNicholl A.G., et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009, 15:1190-1198.
27. Sutherland A.D., Gearry R.B., Frizelle F.A. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 2008, 51:1283-1291.
28. van Rheenen P.F., Van de Vijver E., Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010, 341:c3369.
29. Vermeire S., Van Assche G., Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut 2006, 55:426-431.
30. von Roon A.C., Karamountzos L., Purkayastha S., Reese G.E., Darzi A.W., Teare J.P., et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007, 102:803-813.
31. Jones J., Loftus E.V., Panaccione R., Chen L.S., Peterson S., McConnell J., et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008, 6:1218-1224.
32. Sipponen T., Karkkainen P., Savilahti E., Kolho K.L., Nuutinen H., Turunen U., et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008, 28:1221-1229.
33. Horsthuis K., Bipat S., Bennink R.J., Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology 2008, 247:64-79.
34. Fraquelli M., Sarno A., Girelli C., Laudi C., Buscarini E., Villa C., et al. Reproducibility of bowel ultrasonography in the evaluation of Crohn's disease. Dig Liver Dis 2008, 40:860-866.
35. Girlich C., Jung E.M., Iesalnieks I., Schreyer A.G., Zorger N., Strauch U., et al. Quantitative assessment of bowel wall vascularisation in Crohn's disease with contrast-enhanced ultrasound and perfusion analysis. Clin Hemorheol Microcirc 2009, 43:141-148.
36. Schirin-Sokhan R., Winograd R., Tischendorf S., Wasmuth H.E., Streetz K., Tacke F., et al. Assessment of inflammatory and fibrotic stenoses in patients with Crohn's disease using contrast-enhanced ultrasound and computerized algorithm: a pilot study. Digestion 2011, 83:263-268.
37. Hara A.K., Swartz P.G. CT enterography of Crohn's disease. Abdom Imaging 2009, 34:289-295.
38. Vermeire S., Schreiber S., Sandborn W.J., Dubois C., Rutgeerts P. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 2010, 8:357-363.
39. Surawicz C.M., Belic L. Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease. Gastroenterology 1984, 86:104-113.
40. Pera A., Bellando P., Caldera D., Ponti V., Astegiano M., Barletti C., et al. Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and proposal of an endoscopic score. Gastroenterology 1987, 92:181-185.
41. Moum B., Ekbom A., Vatn M.H., Aadland E., Sauar J., Lygren I., et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93. Scand J Gastroenterol 1997, 32:1005-1012.
42. Bourreille A., Ignjatovic A., Aabakken L., Loftus E.V., Eliakim R., Pennazio M., et al. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy 2009, 41:618-637.
43. Keshet R., Boursi B., Maoz R., Shnell M., Guzner-Gur H. Diagnostic and prognostic significance of serum C-reactive protein levels in patients admitted to the Department of Medicine. Am J Med Sci 2009, 337:248-255.
44. Henriksen M., Jahnsen J., Lygren I., Stray N., Sauar J., Vatn M.H., et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008, 57:1518-1523.
45. Karoui S., Ouerdiane S., Serghini M., Jomni T., Kallel L., Fekih M., et al. Correlation between levels of C-reactive protein and clinical activity in Crohn's disease. Dig Liver Dis 2007, 39:1006-1010.
46. Denis M.A., Reenaers C., Fontaine F., Belaiche J., Louis E. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm Bowel Dis 2007, 13:1100-1105.
47. Wong A., Bass D. Laboratory evaluation of inflammatory bowel disease. Curr Opin Pediatr 2008, 20:566-570.
48. Gisbert J.P., McNicholl A.G., Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis 2009, 15:1746-1754.
49. Koulaouzidis A., Douglas S., Rogers M.A., Arnott I.D., Plevris J.N. Fecal calprotectin: a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy. Scand J Gastroenterol 2011, 46:561-566.
50. Tibble J.A., Sigthorsson G., Foster R., Forgacs I., Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002, 123:450-460.
51. Panes J., Bouzas R., Chaparro M., Garcia-Sanchez V., Gisbert J.P., Martinez de Guerenu B., et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther 2011, 34:125-145.
52. Rimola J., Ordas I., Rodriguez S., Garcia-Bosch O., Aceituno M., Llach J., et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 2011, 17:1759-1768.
53. Steward M.J., Punwani S., Proctor I., Adjei-Gyamfi Y., Chatterjee F., Bloom S., et al. Non-perforating small bowel Crohn's disease assessed by MRI enterography: Derivation and histopathological validation of an MR-based activity index. Eur J Radiol 2012, 81:2080-2088.
54. Rimola J., Rodriguez S., Garcia-Bosch O., Ordas I., Ayala E., Aceituno M., et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 2009, 58:1113-1120.
55. Sauer C.G., Middleton J.P., Alazraki A., Udayasankar U.K., Kalb B., Applegate K.E., et al. Comparison of magnetic resonance enterography (MRE) to endoscopy, histopathology and laboratory evaluation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2012, 55:178-184.
56. Casciani E., Masselli G., Di Nardo G., Polettini E., Bertini L., Oliva S., et al. MR enterography versus capsule endoscopy in paediatric patients with suspected Crohn's disease. Eur Radiol 2011, 21:823-831.
57. Masselli G., Casciani E., Polettini E., Gualdi G. Comparison of MR enteroclysis with MR enterography and conventional enteroclysis in patients with Crohn's disease. Eur Radiol 2008, 18:438-447.
58. Pallotta N., Tomei E., Viscido A., Calabrese E., Marcheggiano A., Caprilli R., et al. Small intestine contrast ultrasonography: an alternative to radiology in the assessment of small bowel disease. Inflamm Bowel Dis 2005, 11:146-153.
59. Gee M.S., Harisinghani M.G. MRI in patients with inflammatory bowel disease. J Magn Reson Imaging 2011, 33:527-534.
60. Karmiris K., Bielen D., Vanbeckevoort D., Vermeire S., Coremans G., Rutgeerts P., et al. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging. Clin Gastroenterol Hepatol 2011, 9:130-136.
61. Vigano C., Losco A., Caprioli F., Basilisco G. Incidence and clinical outcomes of intersphincteric abscesses diagnosed by anal ultrasonography in patients with Crohn's disease. Inflamm Bowel Dis 2011, 17:2102-2108.
62. Dignass A., Van Assche G., Lindsay J.O., Lemann M., Soderholm J., Colombel J.F., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010, 4:28-62.
63. D'Haens G., Van Deventer S., Van Hogezand R., Chalmers D., Kothe C., Baert F., et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999, 116:1029-1034.
64. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
65. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009, 15:1295-1301.
66. De Cruz P., Kamm M.A., Prideaux L., Allen P.B., Moore G. Mucosal healing in Crohn's disease: a systematic review. Inflamm Bowel Dis Apr. 26 2012, [published online]. 10.1002/ibd.22977.
67. Baert F., Moortgat L., Van Assche G., Caenepeel P., Vergauwe P., De Vos M., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468.
68. Casellas F., Barreiro de Acosta M., Iglesias M., Robles V., Nos P., Aguas M., et al. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2012, 24:762-769.
69. Modigliani R., Mary J.Y., Simon J.F., Cortot A., Soule J.C., Gendre J.P., et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990, 98:811-818.
70. D'Haens G.R., Panaccione R., Higgins P.D., Vermeire S., Gassull M., Chowers Y., et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. Am J Gastroenterol 2011, 106:199-212.
71. Boirivant M., Leoni M., Tariciotti D., Fais S., Squarcia O., Pallone F. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 1988, 10:401-405.
72. Filik L., Dagli U., Ulker A. C-reactive protein and monitoring the activity of Crohn's disease. Adv Ther 2006, 23:655-662.
73. Sidoroff M., Karikoski R., Raivio T., Savilahti E., Kolho K.L. High-sensitivity C-reactive protein in paediatric inflammatory bowel disease. World J Gastroenterol 2010, 16:2901-2906.
74. Tilakaratne S., Lemberg D.A., Leach S.T., Day A.S. C-reactive protein and disease activity in children with Crohn's disease. Dig Dis Sci 2010, 55:131-136.
75. Louis E., Vermeire S., Rutgeerts P., De Vos M., Van Gossum A., Pescatore P., et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002, 37:818-824.
76. Jurgens M., Mahachie John J.M., Cleynen I., Schnitzler F., Fidder H., van Moerkercke W., et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011, 9:421-427.
77. Kiss L.S., Szamosi T., Molnar T., Miheller P., Lakatos L., Vincze A., et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther 2011, 34:911-922.
78. Roseth A.G., Aadland E., Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004, 39:1017-1020.
79. Sipponen T., Bjorkesten C.G., Farkkila M., Nuutinen H., Savilahti E., Kolho K.L. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 2010, 45:325-331.
80. Sipponen T., Savilahti E., Karkkainen P., Kolho K.L., Nuutinen H., Turunen U., et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008, 14:1392-1398.
81. Vieira A., Fang C.B., Rolim E.G., Klug W.A., Steinwurz F., Rossini L.G., et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes 2009, 2:221.
82. Mortensen N.J., Ritchie J.K., Hawley P.R., Todd I.P., Lennard-Jones J.E. Surgery for acute Crohn's colitis: results and long term follow-up. Br J Surg 1984, 71:783-784.
83. Lee S.S., Ha H.K., Yang S.K., Kim A.Y., Kim T.K., Kim P.N., et al. CT of prominent pericolic or perienteric vasculature in patients with Crohn's disease: correlation with clinical disease activity and findings on barium studies. AJR Am J Roentgenol 2002, 179:1029-1036.
84. Orel S.G., Rubesin S.E., Jones B., Fishman E.K., Bayless T.M., Siegelman S.S. Computed tomography vs barium studies in the acutely symptomatic patient with Crohn disease. J Comput Assist Tomogr 1987, 11:1009-1016.
85. Zappa M., Stefanescu C., Cazals-Hatem D., Bretagnol F., Deschamps L., Attar A., et al. Which magnetic resonance imaging findings accurately evaluate inflammation in small bowel Crohn's disease? A retrospective comparison with surgical pathologic analysis. Inflamm Bowel Dis 2011, 17:984-993.
86. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500.
87. Louis E., Mary J.Y., Vernier-Massouille G., Grimaud J.C., Bouhnik Y., Laharie D., et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012, 142:63-70.
88. Consigny Y., Modigliani R., Colombel J.F., Dupas J.L., Lemann M., Mary J.Y. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis 2006, 12:551-557.
89. Koelewijn C.L., Schwartz M.P., Samsom M., Oldenburg B. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol 2008, 14:85-89.
90. Costa F., Mumolo M.G., Ceccarelli L., Bellini M., Romano M.R., Sterpi C., et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005, 54:364-368.
91. D'Inca R., Dal Pont E., Di Leo V., Benazzato L., Martinato M., Lamboglia F., et al. Can calprotectin predict relapse risk in inflammatory bowel disease?. Am J Gastroenterol 2008, 103:2007-2014.
92. Garcia-Sanchez V., Iglesias-Flores E., Gonzalez R., Gisbert J.P., Gallardo-Valverde J.M., Gonzalez-Galilea A., et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?. J Crohns Colitis 2010, 4:144-152.
93. Kallel L., Ayadi I., Matri S., Fekih M., Mahmoud N.B., Feki M., et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol 2010, 22:340-345.
94. Tibble J.A., Sigthorsson G., Bridger S., Fagerhol M.K., Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000, 119:15-22.
95. Walker T.R., Land M.L., Kartashov A., Saslowsky T.M., Lyerly D.M., Boone J.H., et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007, 44:414-422.
96. Laharie D., Mesli S., El Hajbi F., Chabrun E., Chanteloup E., Capdepont M., et al. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther 2011, 34:462-469.
97. Olaison G., Smedh K., Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992, 33:331-335.
98. Fazio V.W., Marchetti F. Recurrent Crohn's disease and resection margins: bigger is not better. Adv Surg 1999, 32:135-168.
99. Ryan W.R., Allan R.N., Yamamoto T., Keighley M.R. Crohn's disease patients who quit smoking have a reduced risk of reoperation for recurrence. Am J Surg 2004, 187:219-225.
100. Walters T.D., Steinhart A.H., Bernstein C.N., Tremaine W., McKenzie M., Wolff B.G., et al. Validating Crohn's disease activity indices for use in assessing postoperative recurrence. Inflamm Bowel Dis 2011, 17:1547-1556.
101. Regueiro M., Kip K.E., Schraut W., Baidoo L., Sepulveda A.R., Pesci M., et al. Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis 2011, 17:118-126.
102. Bourreille A., Jarry M., D'Halluin P.N., Ben-Soussan E., Maunoury V., Bulois P., et al. Wireless capsule endoscopy versus ileocolonoscopy for the diagnosis of postoperative recurrence of Crohn's disease: a prospective study. Gut 2006, 55:978-983.
103. Pons Beltran V., Nos P., Bastida G., Beltran B., Arguello L., Aguas M., et al. Evaluation of postsurgical recurrence in Crohn's disease: a new indication for capsule endoscopy?. Gastrointest Endosc 2007, 66:533-540.
104. Scarpa M., D'Inca R., Basso D., Ruffolo C., Polese L., Bertin E., et al. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease. Dis Colon Rectum 2007, 50:861-869.
105. Lamb C.A., Mohiuddin M.K., Gicquel J., Neely D., Bergin F.G., Hanson J.M., et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg 2009, 96:663-674.
106. Sorrentino D., Paviotti A., Terrosu G., Avellini C., Geraci M., Zarifi D. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol 2010, 8:591-599.
107. Koilakou S., Sailer J., Peloschek P., Ferlitsch A., Vogelsang H., Miehsler W., et al. Endoscopy and MR enteroclysis: equivalent tools in predicting clinical recurrence in patients with Crohn's disease after ileocolic resection. Inflamm Bowel Dis 2010, 16:198-203.
108. Minordi L.M., Vecchioli A., Poloni G., Guidi L., De Vitis I., Bonomo L. Enteroclysis CT and PEG-CT in patients with previous small-bowel surgical resection for Crohn's disease: CT findings and correlation with endoscopy. Eur Radiol 2009, 19:2432-2440.
109. Paredes J.M., Ripolles T., Cortes X., Moreno N., Martinez M.J., Bustamante-Balen M., et al. Contrast-enhanced ultrasonography: usefulness in the assessment of postoperative recurrence of Crohn's disease. J Crohns Colitis Apr. 25 2012, [published online]. 10.1016/j.crohns.2012.03.017.
110. Pallis A.G., Mouzas I.A., Vlachonikolis I.G. The inflammatory bowel disease questionnaire: a review of its national validation studies. Inflamm Bowel Dis 2004, 10:261-269.
111. Buxton M.J., Lacey L.A., Feagan B.G., Niecko T., Miller D.W., Townsend R.J. Mapping from disease-specific measures to utility: an analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn's Disease Activity Index in Crohn's disease and measures of utility. Value Health 2007, 10:214-220.
112. Irvine E.J., Zhou Q., Thompson A.K. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol 1996, 91:1571-1578.
113. Sipponen T., Nuutinen H., Turunen U., Farkkila M. Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis 2010, 16:2131-2136.
114. Borthne A.S., Abdelnoor M., Rugtveit J., Perminow G., Reiseter T., Klow N.E. Bowel magnetic resonance imaging of pediatric patients with oral mannitol MRI compared to endoscopy and intestinal ultrasound. Eur Radiol 2006, 16:207-214.
115. Albert J.G., Martiny F., Krummenerl A., Stock K., Lesske J., Gobel C.M., et al. Diagnosis of small bowel Crohn's disease: a prospective comparison of capsule endoscopy with magnetic resonance imaging and fluoroscopic enteroclysis. Gut 2005, 54:1721-1727.
116. Pilleul F., Godefroy C., Yzebe-Beziat D., Dugougeat-Pilleul F., Lachaux A., Valette P.J. Magnetic resonance imaging in Crohn's disease. Gastroenterol Clin Biol 2005, 29:803-808.
117. Horsthuis K., de Ridder L., Smets A.M., van Leeuwen M.S., Benninga M.A., Houwen R.H., et al. Magnetic resonance enterography for suspected inflammatory bowel disease in a pediatric population. J Pediatr Gastroenterol Nutr 2010, 51:603-609.
118. Parisinos C.A., McIntyre V.E., Heron T., Subedi D., Arnott I.D., Mowat C., et al. Magnetic resonance follow-through imaging for evaluation of disease activity in ileal Crohn's disease: an observational, retrospective cohort study. Inflamm Bowel Dis 2010, 16:1219-1226.
119. Lee S.S., Kim A.Y., Yang S.K., Chung J.W., Kim S.Y., Park S.H., et al. Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology 2009, 251:751-761.
120. Siddiki H.A., Fidler J.L., Fletcher J.G., Burton S.S., Huprich J.E., Hough D.M., et al. Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol 2009, 193:113-121.
121. Panaccione R., Loftus E.V., Binion D., McHugh K., Alam S., Chen N., et al. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Can J Gastroenterol 2011, 25:419-425.
122. Van Assche G., Vanbeckevoort D., Bielen D., Coremans G., Aerden I., Noman M., et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 2003, 98:332-339.
123. Villa C., Pompili G., Franceschelli G., Munari A., Radaelli G., Maconi G., et al. Role of magnetic resonance imaging in evaluation of the activity of perianal Crohn's disease. Eur J Radiol 2012, 81:616-622.
124. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.